• Safety Review Committee identified no treatment-related safety concerns in Cohort 1 patients
• Trial allowed to progress to Cohort 2 with 80mg/m2 RC220 dose
• All Cohort 1 patients alive despite advanced metastatic tumour status

Racura Oncology Ltd ('Racura') has received clearance from the Safety Review Committee (SRC) to escalate the RC220 dose in the Phase 1 CPACS trial to the next designated dose level of 80mg/m2. This follows confirmation by the SRC that RC220 showed an acceptable safety profile, with no dose limiting toxicities or safety concerns identified during the safety observation period for the first three Cohort 1 patients dosed at 40mg/m2. Promisingly, all patients on trial are alive despite their advanced metastatic tumour status at the time of enrolment. The study SRC reviewed all safety and pharmacokinetic data from Cohort 1 patients with advanced metastatic solid tumours, who were treated with RC220 alone at 40mg/m2 dose, followed by up to six combination cycles of RC220 at 40mg/m2 and doxorubicin at the standard of care dose of 60mg/m2. Screening of new eligible patients for enrolment in Cohort 2 (80mg/m2 RC220 dose level) is currently underway using an updated trial protocol which includes an initial lead-in safety monotherapy cycle of doxorubicin prior to the administration of RC220. This protocol update enables an assessment of the anthracycline cardioprotective potential of RC220 using a blood-based molecular test.